Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS)
Tianjin, CN
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.79% | +0.54% | +0.30% | -5.32% | -10.47% | -10.74% | +19.84% | -25.94% | +59.00% | +151.20% | +272.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-32.7% Q1'26: +4.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-4.5% Q1'26: +12.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+37.1% ★ Q1'26: +27.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+50.8% ★ Q1'26: +30.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+34.5% ★ Q1'26: +27.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.3% ★ Q1'26: +0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.02× ★ Q1'26: 0.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.08B
est: 7.05B (+0.5%)
|
6.24B
est: 6.66B (-6.3%)
|
5.69B
est: 6.10B (-6.7%)
|
6.36B
est: 6.09B (+4.5%)
|
6.99B
est: 6.78B (+3.1%)
|
6.60B
est: 7.00B (-5.7%)
|
6.91B
est: 7.46B (-7.4%)
|
8.25B
est: 7.94B (+3.9%)
|
8.22B
est: 8.45B (-2.7%)
|
7.31B
est: 9.29B (-21.3%)
|
4.92B
est: 4.91B (+0.2%)
|
5.35B
5.35B – 5.35B
+9.0% YoY
|
5.80B
5.80B – 5.80B
+8.4% YoY
|
| EBITDA |
468.95M
est: 753.29M (-37.7%)
|
330.82M
est: 711.69M (-53.5%)
|
403.78M
est: 652.08M (-38.1%)
|
519.28M
est: 650.47M (-20.2%)
|
625.34M
est: 725.08M (-13.8%)
|
660.90M
est: 748.54M (-11.7%)
|
701.29M
est: 797.36M (-12.0%)
|
786.15M
est: 848.27M (-7.3%)
|
947.65M
est: 903.32M (+4.9%)
|
893.19M
est: 1.79B (-50.2%)
|
2.61B
est: 947.79M (+175.6%)
|
1.03B
1.03B – 1.03B
+9.0% YoY
|
1.12B
1.12B – 1.12B
+8.4% YoY
|
| EBIT |
398.73M
est: 642.21M (-37.9%)
|
260.74M
est: 606.75M (-57.0%)
|
330.98M
est: 555.92M (-40.5%)
|
443.13M
est: 554.56M (-20.1%)
|
528.19M
est: 618.16M (-14.6%)
|
551.04M
est: 638.16M (-13.7%)
|
587.04M
est: 679.78M (-13.6%)
|
671.32M
est: 723.19M (-7.2%)
|
821.03M
est: 770.12M (+6.6%)
|
774.04M
est: 1.63B (-52.6%)
|
2.50B
est: 863.68M (+189.1%)
|
941.11M
941.11M – 941.11M
+9.0% YoY
|
1.02B
1.02B – 1.02B
+8.4% YoY
|
| Net Income |
451.44M
est: 377.98M (+19.4%)
|
423.60M
est: 430.05M (-1.5%)
|
476.08M
est: 455.12M (+4.6%)
|
561.68M
est: 574.94M (-2.3%)
|
625.57M
est: 646.43M (-3.2%)
|
661.70M
est: 673.43M (-1.7%)
|
769.14M
est: 753.65M (+2.1%)
|
861.79M
est: 861.39M (+0.0%)
|
986.71M
est: 1.01B (-2.4%)
|
2.23B
est: 1.14B (+95.8%)
|
2.13B
est: 2.32B (-8.3%)
|
1.12B
1.12B – 1.12B
-51.7% YoY
|
1.24B
1.24B – 1.24B
+10.3% YoY
|
| SGA |
1.60B
est: 2.09B (-23.3%)
|
1.65B
est: 1.97B (-16.4%)
|
1.72B
est: 1.81B (-5.0%)
|
2.00B
est: 1.80B (+10.9%)
|
2.19B
est: 2.01B (+9.2%)
|
1.82B
est: 2.07B (-12.5%)
|
1.93B
est: 2.21B (-12.6%)
|
2.35B
est: 2.35B (-0.1%)
|
2.51B
est: 2.50B (+0.2%)
|
2.46B
est: 2.92B (-15.7%)
|
1.79B
est: 1.54B (+16.1%)
|
1.68B
1.68B – 1.68B
+9.0% YoY
|
1.82B
1.82B – 1.82B
+8.4% YoY
|
| EPS |
0.60
est: 0.49 (+22.4%)
|
0.55
est: 0.56 (-1.3%)
|
0.62
est: 0.59 (+5.1%)
|
0.73
est: 0.75 (-2.1%)
|
0.81
est: 0.84 (-3.3%)
|
0.86
est: 0.87 (-1.5%)
|
1.00
est: 0.98 (+2.4%)
|
1.12
est: 1.12 (+0.3%)
|
1.28
est: 1.31 (-2.3%)
|
2.90
est: 1.48 (+95.9%)
|
2.77
est: 3.02 (-8.3%)
|
1.46
1.46 – 1.46
-51.7% YoY
|
1.61
1.61 – 1.61
+10.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.11% | 39.1K | 0.65% |
| 2 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.02% | 16.9K | 0.55% |
| 3 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 5.2K | 0.15% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 840.2K | 0.06% |
| 5 | Franklin Emerging Market Core Dividend Tilt Index ETF DIEM | 0.01% | 3.8K | 0.19% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 27.2K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 61.4K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 3.03M | 0.06% |
| 9 | JPMorgan BetaBuilders Emerging Markets Equity ETF BBEM | 0.00% | 14.2K | 0.15% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 160.9K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lei Wang | Chairman of the Board | 2M | female |
| Hong Zhou | Deputy GM, Chief Engineer & Executive Director | 1M | male |
| Yu Zhang | Chief Manufacturing Officer | 1M | male |
| Mingjie Shang | Employee Director | 1M | male |
| Jian Ma | Chief Financial Officer | 1M | male |
| Min Guo | Executive Director | — | male |
| Hong Chen | Executive Vice President | — | male |
| Tang Chao | Accounting Supervisor | — | — |
| Yan Jiao | Secretary to the Board of Directors | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600329.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
